Bibliography for Item 12 in BGP: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
(New page: What You Can Learn from Managers in Biotech http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=U9705A&_requestid=6230 The Value of Openness in Scientific Pr...)
 
 
(7 intermediate revisions by the same user not shown)
Line 1: Line 1:
What You Can Learn from Managers in Biotech
==Used Resources==
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=U9705A&_requestid=6230


The Value of Openness in Scientific Problem Solving
*Prewitt, Edward, ''What You Can Learn from Managers in Biotech'', Harvard Management Update, May 1 1997, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=U9705A&_requestid=6230
No. 07-050
Karim R. Lakhani and Lars Bo Jeppesen, Peter A. Lohse and Jill A. Panetta
Technology and Operations Management
January 2007
Complete Text (Acrobat PDF Version) Openness and free information sharing amongst scientists are supposed to be core norms of the scientific community. However, many studies have shown that these norms are not universally followed. Lack of openness and transparency means that scientific problem solving is constrained to a few scientists who work in secret and who typically fail to leverage the entire accumulation of scientific knowledge available. We present evidence of the efficacy of problem solving when disclosing problem information. The method’s application to 166 discrete scientific problems from the research laboratories of 26 firms is illustrated. Problems were disclosed to over 80,000 independent scientists from over 150 countries. We show that disclosure of problem information to a large group of outside solvers is an effective means of solving scientific problems. The approach solved one-third of a sample of problems that large and well-known R & D-intensive firms had been unsuccessful in solving internally. Problem-solving success was found to be associated with the ability to attract specialized solvers with range of diverse scientific interests. Furthermore, successful solvers solved problems at the boundary or outside of their fields of expertise, indicating a transfer of knowledge from one field to others.
58 pages


The Life Sciences Revolution: A Technical Primer
*Lakhani, Karim R. and Lars Bo Jeppesen, Peter A. Lohse and Jill A. Panetta, ''The Value of Openness in Scientific Problem Solving'', Technology and Operations Management, No. 07-050, January 2007.
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=602118&_requestid=6269
**Complete Text (Acrobat PDF Version) Openness and free information sharing amongst scientists are supposed to be core norms of the scientific community. However, many studies have shown that these norms are not universally followed. Lack of openness and transparency means that scientific problem solving is constrained to a few scientists who work in secret and who typically fail to leverage the entire accumulation of scientific knowledge available. We present evidence of the efficacy of problem solving when disclosing problem information. The method’s application to 166 discrete scientific problems from the research laboratories of 26 firms is illustrated. Problems were disclosed to over 80,000 independent scientists from over 150 countries. We show that disclosure of problem information to a large group of outside solvers is an effective means of solving scientific problems. The approach solved one-third of a sample of problems that large and well-known R & D-intensive firms had been unsuccessful in solving internally. Problem-solving success was found to be associated with the ability to attract specialized solvers with range of diverse scientific interests. Furthermore, successful solvers solved problems at the boundary or outside of their fields of expertise, indicating a transfer of knowledge from one field to others. 58 pages


Innovation and Leadership Values
*Pisano, Gary P., Stephanie Oestreich, Clarissa Ceruti, ''The Life Sciences Revolution: A Technical Primer'', January 28, 2002 http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=602118&_requestid=6269
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=CMR385&_requestid=7630


Learning From Collaboration: Knowledge and Networks in the Biotechnology and Pharmaceutical Industries
*Miles, Raymond, ''Innovation and Leadership Values'', November 1, 2007, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=CMR385&_requestid=7630
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=CMR117&_requestid=5010


The Performance of the Biotech Industry: Promise Versus Reality
*Powell, Walter, ''Learning From Collaboration: Knowledge and Networks in the Biotechnology and Pharmaceutical Industries'', CMR April 1, 2008, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=CMR117&_requestid=5010
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=6608BC&_requestid=5019


The Monetization of Intellectual Property: The Forces that Drive the Business of Biotechnology
*Pisano, Gary P., ''The Performance of the Biotech Industry: Promise Versus Reality'', HBS Press Chapter, November 14, 2006, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=6608BC&_requestid=5019
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=6609BC&_requestid=5023


The Science-Based Business: A Novel Experiment  
*Pisano, Gary P., ''The Monetization of Intellectual Property: The Forces that Drive the Business of Biotechnology'', HBS Press Chapter, November 14, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=6609BC&_requestid=5023
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=6534BC&_requestid=5539
 
*Pisano, Gary P., ''The Science-Based Business: A Novel Experiment'', HBS Press Chapter, November 14, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=6534BC&_requestid=5539


(I have this Pisano's book - Science Business...It is worth reading to find information about the field)  
(I have this Pisano's book - Science Business...It is worth reading to find information about the field)  
''Brendan: got it from the library. very helpful''
<br>
*Lehrer, Mark, ''Kazuhiro Asakawa Pushing Scientists into the Marketplace: Promoting Science Entrepreneurship'', CMR, May 1, 2004. http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=CMR284&_requestid=6247
*Binder, Gordon, Philip Bashe ''Science Lessons: What the Business of Biotech Taught Me About Management'', Cambridge: Harvard Business School Press, 2008. http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=8614&_requestid=6530


Pushing Scientists into the Marketplace: Promoting Science Entrepreneurship
*Hayes, Robert H., Perry L. Fagan, ''The Pharma Giants: Ready for the 21st Century?'', May 6, 1998, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=698070&_requestid=5868
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=CMR284&_requestid=6247


Science Lessons: What the Business of Biotech Taught Me About Management
*Yoffie, David B., Dharmesh M. Mehta, Rachel T. Sha ''Note on the Convergence Between Genomics & Information Technology'', May 15, 2005, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=705500&_requestid=5904
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=8614&_requestid=6530


The Pharma Giants: Ready for the 21st Century?
* Eaton, Margaret L., ''Novartis-U.C. Berkeley Research Collaboration'', April 1, 2004, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=BME7&_requestid=5636
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=698070&_requestid=5868


Note on the Convergence Between Genomics & Information Technology
*George, William W., Andrew N. McLean, ''Kevin Sharer at Amgen: Sustaining the High-Growth Company (A)'', October 5, 2005 http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=406020&referral=2342
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=705500&_requestid=5904


Novartis-U.C. Berkeley Research Collaboration
* Henkel, Joachim, Markus Reitzig, ''Patent Sharks'', Harvard Business Review, June 1, 2008, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=R0806J&_requestid=6985
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=BME7&_requestid=5636


Kevin Sharer at Amgen: Sustaining the High-Growth Company (A)
* Wright, Randall, ''How to Get the Most From University Relationships'', April 1, 2008, http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=SMR282&_requestid=7622
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=406020&referral=2342


Patent Sharks
* Lazier, William C., Kevin Taweel,  John W. Glynn Jr. ''Gilead Sciences'', Stanford Graduate School of Business, 1993, https://gsbapps.stanford.edu/cases/detail1.asp?Document_ID=1357
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=R0806J&_requestid=6985


How to Get the Most From University Relationships
* Rohan, Dennis M., Alicia Seiger ''Note On The Biopharmaceutical Industry'', Stanford Graduate School of Business, 2003, https://gsbapps.stanford.edu/cases/detail1.asp?Document_ID=1785
http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=SMR282&_requestid=7622
**You probably can get this through your University. If you can't ask Roxy the favor of downloading this papers and sending to you. She is a RA in Aarons group that also work in HBS. Her email is "Roxanna Myhrum" <rmyhrum@cyber.law.harvard.edu> and "Roxanna Myhrum" <rox.myhrum@gmail.com>.


Gilead Sciences
* A Kernel for Open Source Drug Discovery in Tropical Diseases, Leticia Ortı, www.plosntds.org, April 2004, Vol. 3 Is. 4
https://gsbapps.stanford.edu/cases/detail1.asp?Document_ID=1357


Note On The Biopharmaceutical Industry
==Navigation==
https://gsbapps.stanford.edu/cases/detail1.asp?Document_ID=1785You probably can get this through your University. If you can't ask Roxy the favor of downloading this papers and sending to you. She is a RA in Aarons group that also work in HBS. Her email is "Roxanna Myhrum" <
[[Open Business models in BGP]]<br>
rmyhrum@cyber.law.harvard.edu> and "Roxanna Myhrum" <rox.myhrum@gmail.com>.
[[Biotechnology_-_Genomic_and_Proteomics]]

Latest revision as of 12:29, 3 May 2009

Used Resources

  • Lakhani, Karim R. and Lars Bo Jeppesen, Peter A. Lohse and Jill A. Panetta, The Value of Openness in Scientific Problem Solving, Technology and Operations Management, No. 07-050, January 2007.
    • Complete Text (Acrobat PDF Version) Openness and free information sharing amongst scientists are supposed to be core norms of the scientific community. However, many studies have shown that these norms are not universally followed. Lack of openness and transparency means that scientific problem solving is constrained to a few scientists who work in secret and who typically fail to leverage the entire accumulation of scientific knowledge available. We present evidence of the efficacy of problem solving when disclosing problem information. The method’s application to 166 discrete scientific problems from the research laboratories of 26 firms is illustrated. Problems were disclosed to over 80,000 independent scientists from over 150 countries. We show that disclosure of problem information to a large group of outside solvers is an effective means of solving scientific problems. The approach solved one-third of a sample of problems that large and well-known R & D-intensive firms had been unsuccessful in solving internally. Problem-solving success was found to be associated with the ability to attract specialized solvers with range of diverse scientific interests. Furthermore, successful solvers solved problems at the boundary or outside of their fields of expertise, indicating a transfer of knowledge from one field to others. 58 pages

(I have this Pisano's book - Science Business...It is worth reading to find information about the field) Brendan: got it from the library. very helpful

  • Rohan, Dennis M., Alicia Seiger Note On The Biopharmaceutical Industry, Stanford Graduate School of Business, 2003, https://gsbapps.stanford.edu/cases/detail1.asp?Document_ID=1785
    • You probably can get this through your University. If you can't ask Roxy the favor of downloading this papers and sending to you. She is a RA in Aarons group that also work in HBS. Her email is "Roxanna Myhrum" <rmyhrum@cyber.law.harvard.edu> and "Roxanna Myhrum" <rox.myhrum@gmail.com>.
  • A Kernel for Open Source Drug Discovery in Tropical Diseases, Leticia Ortı, www.plosntds.org, April 2004, Vol. 3 Is. 4

Navigation

Open Business models in BGP
Biotechnology_-_Genomic_and_Proteomics